10x Genomics (TXG) Q1 FY26 earnings call

10x Genomics reported a solid start to the year, marked by strong sales momentum and the highly anticipated launch of its Atera instrument platform, which has garnered extraordinary customer response. The company is navigating a challenging capital equipment environment and expects near-term revenue cadence to reflect customer anticipation for Atera, while maintaining its full-year outlook. Management emphasized the long-term potential of AI-driven research and translational applications as key growth drivers for its single cell and spatial technologies.